DICE — Dice Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
DICE Therapeutics up on promising data of skin disease drug
Brief: Dice Therapeutics Announces Positive Topline Data From Phase 1 Clinical Trial Of Lead Oral Il-17 Antagonist, Dc-806, For Psoriasis
Brief: Dice Therapeutics Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing
Amgen, Dice Therapeutics fall after rival psoriasis drug approval
Dice Therapeutics rises after Stifel initiates coverage with 'buy'
Brief: Dice Therapeutics Reports Second Quarter 2022 Financial Results And Recent Highlights
Brief: Dice Therapeutics Announces Completion Of Enrollment In Phase 1 Clinical Trial Of Lead Oral IL-17 Antagonist, DC-806, For The Treatment Of Psoriasis
Dice Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Dice Therapeutics Reports Q1 Loss Per Share Of $0.50
Brief: ShouTi Appoints Sharon Tetlow To Board
Brief: DICE Therapeutics Says Sanofi Sent Notice To Co That It Has Elected To Terminate The Sanofi Agreement
Brief: DICE Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Brief: Dice Therapeutics Inc Initiates Phase 1 Clinical Trial Of S011806 For The Treatment Of Psoriasis
Live Markets: IPO market off to the races
Federer-backed On sprints higher after impressive debut
Brief: Dice Therapeutics Inc Shares Open 76.5% Above IPO Price In Nasdaq Debut
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:59 AM
Brief: Dice Molecules Holdings Says Pricing Of Upsized Initial Public Offering Of 12,000,000 Shares Of Common Stock At $17/Share
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM